The S&P 500 was on track for double-digit earnings growth, with more than half of companies having reported Q4 results so far.

Novo Nordisk is suing a Shrewsbury doctor who sells a cheaper compounded medicine version of its popular Ozempic and Wegovy ...

Hims & Hers executives struck a confident tone about the company's growth prospects on Monday as it launches new specialties and expands rapidly into international markets. | Investors are concerned ...

Hims & Hers Health is facing existential risk as regulatory uncertainty and margin erosion undermine its growth narrative. Click here to read why HIMS is a Sell.

What are you watching for in tonight’s State of the Union address? Let me know what you flag during the speech — and how it ...

Shares of Hims & Hers Health (NYSE:HIMS) are trading lower this morning after yesterday’s earnings, and the reason is ...

HIMS stock is currently trading at levels last seen in September 2024 and has fallen over 50% year-to-date.

Hims & Hers Health, Inc., faces GLP-1 headwinds, volatility, and regulatory risk but has strong revenue growth and global ...

Hims & Hers Health stock fell after the telehealth company posted mixed quarterly results and issued a weak outlook for the current quarter.

Hims & Hers Health (NYSE: HIMS) delivered a beat on both earnings and profitability in Q4 2025, though a soft 2026 revenue ...

Hims & Hers stock drops after Q4 revenue miss. Outlook trails estimates despite profit beat and strong subscriber growth.

Novo Nordisk will slash U.S. list prices of its blockbuster diabetes and weight-loss drugs Ozempic and Wegovy by up to 50% ...